0001493152-24-025093.txt : 20240625 0001493152-24-025093.hdr.sgml : 20240625 20240625161517 ACCESSION NUMBER: 0001493152-24-025093 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240625 ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240625 DATE AS OF CHANGE: 20240625 FILER: COMPANY DATA: COMPANY CONFORMED NAME: VBI Vaccines Inc/BC CENTRAL INDEX KEY: 0000764195 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37769 FILM NUMBER: 241069141 BUSINESS ADDRESS: STREET 1: 160 SECOND STREET STREET 2: CAMBRIDGE CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-830-3031 MAIL ADDRESS: STREET 1: 160 SECOND STREET STREET 2: CAMBRIDGE CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: SciVac Therapeutics Inc. DATE OF NAME CHANGE: 20150717 FORMER COMPANY: FORMER CONFORMED NAME: LEVON RESOURCES LTD. DATE OF NAME CHANGE: 20100910 FORMER COMPANY: FORMER CONFORMED NAME: LEVON RESOURCES LTD DATE OF NAME CHANGE: 19850305 8-K 1 form8-k.htm
false 0000764195 VBI Vaccines Inc/BC 0000764195 2024-06-25 2024-06-25 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of report (Date of earliest event reported): June 25, 2024

 

VBI VACCINES INC.

(Exact name of registrant as specified in its charter)

 

British Columbia, Canada   001-37769   N/A

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

160 Second Street, Floor 3

Cambridge, Massachusetts

   02142
(Address of principal executive offices)   (Zip Code)

 

(617) 830-3031

(Registrant’s telephone number, including area code)

 

N/A

(Former Name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of exchange on which registered
Common Shares, no par value per share   VBIV   The NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 5.07 Submission of Matters to a Vote of Security Holders.

 

On June 25, 2024, VBI Vaccines Inc. (the “Company”) held its 2024 Annual General Meeting of Shareholders (the “Annual Meeting”). At the Annual Meeting, the shareholders voted to: (1) elect the nominated directors of the Company to serve until the next annual meeting of shareholders or until the appointment or election and qualification of their successors and (2) approve the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm until the next annual meeting of shareholders and to authorize the audit committee (the “Audit Committee”) of the board of directors of the Company to fix EisnerAmper LLP’s remuneration, as set forth in the Company’s definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 29, 2024 (the “Proxy Statement”). Each of these proposals is described in more detail in the Proxy Statement.

 

At the beginning of the Annual Meeting, there were 13,879,327 common shares present at the Annual Meeting in person or by proxy, which represented 48.39% of the outstanding common shares entitled to vote at the Annual Meeting and which constituted a quorum for the transaction of business. Holders of the Company’s common shares were entitled to one vote for each share held as of the close of business on April 26, 2024, the record date for the Annual Meeting.

 

The voting results on these proposals were as follows:

 

Proposal 1: Election of eight directors

 

Director  Votes For   Withheld   Broker Non-Votes 
Steven Gillis   3,663,424    882,856    9,333,047 
Damian Braga   3,651,602    892,907    9,334,818 
Joanne Cordeiro   3,776,579    769,703    9,333,045 
Michel De Wilde   3,625,156    919,353    9,334,818 
Vaughn Himes   3,813,210    733,071    9,333,046 
Blaine H. McKee   3,778,849    767,432    9,333,046 
Jeffrey R. Baxter   3,685,583    858,927    9,334,817 
Nell Beattie   3,714,249    830,260    9,334,818 

 

Each of the eight nominees for director was elected to serve until the next annual meeting of shareholders and until his or her successor has been elected and qualified, or until his or her earlier death, resignation, or removal.

 

Proposal 2: Approval of the appointment of EisnerAmper LLP as the independent registered public accounting firm of the Company until the next annual meeting of shareholders and to authorize the Audit Committee to fix EisnerAmper LLP’s remuneration

 

Votes For  Votes Against   Abstentions   Broker Non-Votes 
12,931,798   

0

    

947,529

    

0

 

 

 

 

 

The shareholders approved the appointment of EisnerAmper LLP as the Company’s independent registered public accounting firm until the next annual meeting of shareholders and authorized the Audit Committee to fix EisnerAmper LLP’s remuneration.

 

Item 8.01 Other Events.

 

On June 25, 2024, the Company issued a press release announcing the voting results from the Annual Meeting. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits

 

Exhibit No.   Description
     
99.1   Press Release dated June 25, 2024
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  VBI Vaccines Inc.
     
Date: June 25, 2024 By: /s/ Jeffrey R. Baxter
    Jeffrey R. Baxter
    President and Chief Executive Officer

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

VBI Vaccines Announces Results of Annual General Meeting

 

CAMBRIDGE, Mass. (June 25, 2024) – VBI Vaccines Inc. (Nasdaq: VBIV) (“VBI” or the “Company”), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced the voting results from its annual general meeting of shareholders held on June 25, 2024 (the “Meeting”).

 

The total number of common shares of the Company (“Common Shares”) represented by shareholders (“Shareholders”) present in person or represented by proxy at the Meeting was an aggregate of 13,879,327 Common Shares, representing 48.39% of VBI’s issued and outstanding Common Shares as of the record date for the Meeting, April 26, 2024.

 

The voting results with respect to each of the following eight director nominees, as described in the Company’s proxy statement dated April 29, 2024 (the “Proxy Statement”), all of whom previously served as directors of the Company, were as follows:

 

Nominee  Votes For   %   Votes Withheld   % 
Steven Gillis   3,663,424    80.58%   882,856    19.42%
Damian Braga   3,651,602    80.35%   892,907    19.65%
Joanne Cordeiro   3,776,579    83.07%   769,703    16.93%
Michel De Wilde   3,625,156    79.77%   919,353    20.23%
Vaughn Himes   3,813,210    83.88%   733,071    16.12%
Blaine H. McKee   3,778,849    83.12%   767,432    16.88%
Jeffrey R. Baxter   3,685,583    81.10%   858,927    18.90%
Nell Beattie   3,714,249    81.73%   830,260    18.27%

 

The Shareholders also voted in favor of appointing EisnerAmper LLP as VBI’s independent registered public accounting firm until the next annual meeting of shareholders and authorizing the audit committee of VBI’s board of directors to fix its remuneration.

 

Additional information regarding the results of all matters voted upon at the Meeting may be found in the Company’s SEC and SEDAR filings.

 

About VBI Vaccines Inc.

 

VBI Vaccines Inc. (“VBI”) is a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease. Through its innovative approach to virus-like particles (“VLPs”), including a proprietary enveloped VLP (“eVLP”) platform technology and a proprietary mRNA-launched eVLP (“MLE”) platform technology, VBI develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. VBI is committed to targeting and overcoming significant infectious diseases, including hepatitis B, coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). VBI is headquartered in Cambridge, Massachusetts, with research operations in Ottawa, Canada, and a research and manufacturing site in Rehovot, Israel.

 

Website Home: http://www.vbivaccines.com/

News and Resources: http://www.vbivaccines.com/news-and-resources/

Investors: http://www.vbivaccines.com/investors/

 

VBI Investor and Media Contact

 

Amy Sharpe
Phone: (617) 830-3031 x151
Email: IR@vbivaccines.com

 

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 4 vbiv-20240625.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 vbiv-20240625_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 vbiv-20240625_pre.xml XBRL PRESENTATION FILE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Cover
Jun. 25, 2024
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Jun. 25, 2024
Entity File Number 001-37769
Entity Registrant Name VBI Vaccines Inc/BC
Entity Central Index Key 0000764195
Entity Incorporation, State or Country Code A1
Entity Address, Address Line One 160 Second Street
Entity Address, Address Line Two Floor 3
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02142
City Area Code (617)
Local Phone Number 830-3031
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Shares, no par value per share
Trading Symbol VBIV
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.1.u2 html 1 22 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://vbivaccines.com/role/Cover Cover Cover 1 false false All Reports Book All Reports [dq-60547-EntityTaxIdentificationNumber-Missing] Submission type 8-K should have a non-empty value for EntityTaxIdentificationNumber in the Required Context. form8-k.htm [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 1 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName - form8-k.htm 21 form8-k.htm vbiv-20240625.xsd vbiv-20240625_lab.xml vbiv-20240625_pre.xml http://xbrl.sec.gov/dei/2024 true false JSON 16 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "VBIV", "nsuri": "http://vbivaccines.com/20240625", "dts": { "inline": { "local": [ "form8-k.htm" ] }, "schema": { "local": [ "vbiv-20240625.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "labelLink": { "local": [ "vbiv-20240625_lab.xml" ] }, "presentationLink": { "local": [ "vbiv-20240625_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2024": 3 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 22 }, "report": { "R1": { "role": "http://vbivaccines.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-06-25", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-06-25", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentDescription", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AnnualInformationForm", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CountryRegion", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAccountingStandard", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodStartDate", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentRegistrationStatement", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentShellCompanyReport", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine3", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCountry", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPrimarySicNumber", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Extension", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "NoTradingSymbolFlag", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12gTitle", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityReportingObligation", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://vbivaccines.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 17 0001493152-24-025093-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-24-025093-xbrl.zip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end XML 19 form8-k_htm.xml IDEA: XBRL DOCUMENT 0000764195 2024-06-25 2024-06-25 iso4217:USD shares iso4217:USD shares false 0000764195 VBI Vaccines Inc/BC 8-K 2024-06-25 A1 001-37769 160 Second Street Floor 3 Cambridge MA 02142 (617) 830-3031 false false false false Common Shares, no par value per share VBIV NASDAQ false